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The synthetic r¢tinoid fenretinide C4-HPR: N.[4.hydroxyphenyl] all.tra,s.r¢tina~rnide) lntcra=ts with plasma apo-retinol-bindin8 protein (RBP) to 
form a tiliht ¢ompl~ (A~... 0.2/JM) which do~ not exhibit binding affinity to tran,qhyretin (TTR). Therefore. a substantial modif~tion of tho 
retinol hydroxyl group does not a,~p~r to alT~t the interaction with RBP but dot~ drastically interfere with the protein-protein ro¢o~nition. The 
remarkable ~trly reduction in pin m'm r¢tinoi level induced by I'enretinide administration may be at~;o¢iated with the hilih bindinil afflnit~t of this 
retinoid to RBP and to its interference with the RBP-TTR compl=x formation. 
Retinol.bintlin= protein; Fcnrctinid¢: N.Ethylretinamid¢; Retinoid bindinlF Tran=thyretin; Plasma retinol level 
I, INTRODUCTION 
Retinol-bit~ding protein (RBP) is a well..chara¢terizcd 
protein which transports r¢tinol in plasma [1,2]. It ¢on- 
si,¢ts eta single po[ypeptide chain of 21 kDa which binds 
one molecule of' retinol. RBP interacts in plasma with 
thyroxine-bindinl~ transthyretin CTTR), a homotetra- 
mer of reel. wt. 55 kDa. The delivery of rctinol to cell- 
surface receptors of target cells [3] is believed to induce 
conformational changes in the RBP molecule responsi- 
ble for the reduction of' its binding affinity to TTR [1]. 
Thus, owing to its small size, free uncomplexed plasma 
apo.RBP can undergo ready filtration and degradation 
in the kidney [4], 
The retinol-binding site of' RBP can aeeomodat= a 
variety ot" analogs ot the natural |igand [1]. The admin- 
istration of pharmacologically active retinoids raises the 
question of their possible binding to RBP which might 
cause an interference with the secretion and/or trans- 
port of retinol in plasma. Such a mechanism may be 
involved in the substantial reduction in retinol and RBP 
plasma levels induced by fenretinide [5], a retinoid 
which is effective in inhibiting carcinogenesis n experi- 
mental animals [6]. In this work we have established 
that fenretinide interacts with P, BP to form a tight corn- 
Abbreviations: RPB, r¢tinol-blading protein; 'i~R, transthyretin. 
Correspondence address: R, Berni, tstltuto dl S¢ienzc Biochimiche, 
Universit',l di Parma. Yial¢ dell= Scienz=. 1-43100 Parma, It:fly, Fe~: 
(39) (521) 580 665. 
plex which lacks binding affinity to TI'R. Them interac- 
tions might be related to the influence of fenretinide on 
plasma retinol level. 
2. MATERIALS AND METHODS 
2,1, Materials 
Human and bovine holo-RBP and TTR were pudlied from f r~ 
plasma as dci¢ribed [7-91 and were qu'antifu~l at 280 nm udnll al:~orp 
lion ¢o¢l/i¢ients s~ A~¢. of 18,6 and 14.3, r~pectively. Apo-RBP w~ 
prepared by extracting retinol from holo.RtaP with dieth:dether [I0]. 
Human TTR-Sepharose 4B affinity r~in was prepared as dercribcd 
[I tJ. Fenreti,dd¢ (4-HPR, N-H-hydroxy- phenyl]all.trans.retinamidc) 
and all.trans.N-cthylretinamide we.re tlifts from R.W, Johnson Phar- 
maceutical Research institute (Pa, USA) and from F. Hoffman.La 
Roche (Ba~l, Swit~rland), resi:nctively, CNBr-activated Sepharar¢ 
4B and Scphadex G-S0 Fine wcr¢ purehaP-..d from Pharma¢ia 
(Upp~la. Sweden). 
2.2, Fluorescence hhJdin~t ussa), 
Fenretinid¢ binding to human apo.RDP was monitored by follow- 
ing the quenching of protein fluoresc..~nce as dcKribcd [lOl. 
2.3, Preparatim~ offenretinide.RDP and retinol.RgP complexes 
A 2x molar exc¢~ of I'enretinide or ~tinol w~ incubated with 
human apo-RBP (S0 nmol in O,S ml) in 0,05 M sodium ph~phatc, 0 15 
M NaCI. pH 7, at 20"C for 1 h, The rct,aoid-RBP complex was then 
separated from the exe.~s retinoid by ehromatog, mphy on a 5¢phadex 
G-50 Fine column, 
2.4, In viva treatment a td plasma retinal concentration assay 
Female Sprague-Dawley rats {150-170 8) (Charl¢~ River, C.al¢o, 
Italy) were treated by intubation with fenrctinide or N.ethylretinamid= 
suzpcnded inr~,am= oil at the do~..fY0 mB/kll. Control rats received 
~sam¢ oil. Three rats i~r group ware u.~:d, Blood was drav~l at tim= 
0. 5 and 24 h alter treatment. Plasma rctinol e.on~ntration.~ were 
assayed by hil~h performance liquid chromatography (HPLC) as pr¢. 
viottsly de~,eribed [5]. 
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Fil~. I. Titration of human apo.R UP with fcnrctinide, "rhc intc,sity of 
protein Iluoresecnc¢ is plotted as u I't,nctiott o[. I'cnrctinide concentnt- 
tlon, "i'lze in~t =l~ov,'s the Scatchard plot of the d.'tttt, Conditions: 0.5 
,uM RBP in 0,0~ M sodium phosphate, 0, I S M NaCI, pH T, at 's0*C. 
Protein fluorescence was monitored at 335 nm with cxcitz.ttJon ztt 
2~S nm, 
3. RESULTS AND DISCUSSION 
3.1. [nteracfi#n offenrethtM¢ with apo-RBP 
The addition of fenretinide to apo-RBP causes a 
marked quenching of tryptophan fluorescence, due to 
efficient energy transfer to the bound retinoid. A typical 
fluorescence titration curve of human apo-RBP with 
fcnmtinidc is shown in FiB. 1. It is apparent from the 
Seatchard plot [12] that the bindinl~ data are well fitted 
on the basis of one binding site for fenretinide, with an 
apparent dissocir, tion constant o'" 0.1 ?/.tM at 20"C (Fig. 
1, inset). A binding affinity to apo-RBP similar to that 
previously found for rctinol is consistent with the con- 
clusion that the modification o f  the retinol hydroxyl 
~roup does not significantly affect the interaction of 
retinoids with RBP [10]. 
3.2. Lack of hztcractiutt ofthe fenrethtid¢-RBP cumpl¢.~ 
u.ith TTR 
The fenretinide-RBP complex, whose absorption 
spectrum is shown in the inset of Fig. 2, was subjected 
to chromatography on u human "l'TR-Sepharose 413 
affinity column. Its elution volume was similar to that 
of the control, bovine serum albumin (FIB. 2), indicating 
the lack of a significant binding affinity to TTR at 
'physiological' ionic strength, by contrast with the re- 
tention of native or reconstituted retinol-RBP com- 
plexes, which were ¢lutcd from the column only at very 
low ionic strength (Fig. 2) [13]. We have also verified 
that the interactions of fenretinide with the bovine 
RBP-TTR system are quite similar to those established 
for the human RBP-TTR system (data not shown). 
Therefore, the binding properties that we have pre- 
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Fi~.. 2, Affinity ch,~om,toilraphy of the fcnrctinidc-RBP complex on 
q-l'R-Sepharos¢ 4B. 10.-20 nmol of" fcnretinide.(human}RBP or 
human rctinol-RBP complexes were applied to the human TTR cou. 
pied to Scpharosc 4B affinity column (IxS cm) [l 1,13]. equilibrated 
with 0,05 M sodium phosplmtc. 0,15 M NaCl, pH 7, Elation ",~as 
performed at a 0,2 ml/min flow rate with the =tree buffer [.,~r the 
fcnrctinidc-RBP complex, ~nd with u linear iiradicnt from this bulTcr 
to 0,001 M r, odium phosphate, pH 7, for the rctinoI-RBP complex. 
The elution prol'llcs were monitored by nbsorbanccs at 355 and 330 
,tm ['or ['cnretinidc-RBP (O) and native retinoI-RBP (~) complexes. 
r~p;¢tivcly, and by absorbancc at 280 nm for the control bovine 
serum albumin (CI). The elation profile ['or the retinol-RBP complex 
obtained by the bindinil, of rctinol to apo.RBP, which i~ ahnost coin- 
cideitt with that of the native retinol-Rnpcomplex, is nlr, o shown (A). 
(Inset) Absorption spectrum of the fcnrctinide-RL1P complex, in 
0.0S M sodium phosphate. 0,IS M NaCI, pH 7. 
seated presumably represent n general feature and may 
be extended to other mammalian RBP-TTR systems as 
well. 
3.3, The hucractian of fcm'¢th;ide with RBP in relation 
to its h~htence ore plasma rethw[ concetm'atiot~ 
The administration of fenretinide induces a substan- 
tial early reduction in plasma retinol concentration both 
in rats (Table I) 1"14] and in humans [5]. A similar effect 
has also been found for N-cthylrctinamid¢ (Table I), 
whose binding properties in the interaction with the 
RBP-TTR system arc very close to those of fenretinide 
(R. Berni, unpublished results). The lowering of plasma 
retinol levels might be associated with symptoms of 
Table 1 
Effect of [.cnrctinidc and/V.ethylrctinamide on plasma rctinol conccn, 
tration in rats" 
Treatment Retino! plasma concentration 
(ng/ml) 
0 h S h 24 h 
None 324 + 24 313 .29  317 '*" 25 
Ironrotin:do 297 + 16 126 ± 14 94 + ? 
N-Ethylrctinamidc 3~4 + 83 182 .+ 34 234 ~" 17 
"Three rat~ for each groups; means ¢ S,D. 
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vitamin A deprivation observed after treatment with 
fenretinide [15], We suggest that the reduction in plasma 
rctinol levels is related to the high binding affinity of 
fenretinide and N-¢thylretinamide to RBP, which may 
re.suit in a competition with retinol tbr the RBP retinol- 
binding site. Accorctingly, fenretinide- and N-ethylrcti- 
namide-RBP complexes might bc formed in plasma. 
Du¢ to the lack of binding affinity to TTR, they might 
be subsequently cleared by glomerular filtration. Even 
more relevant might be the competition of the two reti- 
noids with retinol for RBP in the hepatocyte, before the 
secretion of RBP itselC. After fenretinide administration 
plasma R BP decreases proporl ionally to retinol [5], thus 
sag$¢sting that the competition results in an interfer- 
ence with the retinol-RBP secretion into the blood. This 
hypothesis in accordance with the previous observa- 
tions that the secretion of RBP is strictly dependent on 
the availability of rctinol [i] and is ¢tTc~:tivciy inhibited 
by several retinoids in cultured liver cells [16]. 
Aek~t~tt'le#~¢~ts: Thi~ w.ork wa~ ~upported by the= CNR Tar@| ProS. 
~t in Biot¢¢hnoloj> and Bioinstrumcntadon (Rom¢. tealy). 
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